Company Encyclopedia
View More
name
Takeda Pharmaceutical Co. Ltd.
4502.JP
News
View More

Seattle startup Accipiter Bio emerges with $12.7M and big pharma deals for AI-designed proteins

Seattle startup Accipiter Bio has raised $12.7 million and formed partnerships with Pfizer and Kite Pharma to develop AI-designed proteins targeting diseases. The company, emerging from a Nobel laureate's lab, aims to create multifunctional drugs that can bind multiple cellular targets, potentially improving treatment efficacy and reducing FDA approval costs. Accipiter has four drug-development programs, with two nearing FDA discussions. The funding round was co-led by Flying Fish Partners and Takeda, with additional investors including Columbus Venture Partners and Washington Research Foundation.

GeekWire·
4502
0.00%
US
PFE
+4.59%
GeekWire·
4502
0.00%
US
PFE
+4.59%

Takeda Shares Promising Interim Results For Mezagitamab In IgA Nephropathy

Takeda Pharmaceutical Company Limited (TAK) announced promising interim results from its Phase 1b trial of mezagitamab (TAK-079) for IgA nephropathy. The study showed stable kidney function, measured by estimated glomerular filtration rate (eGFR), maintained through Week 96, up to 18 months post-treatment. These findings were presented at the ASN Kidney Week 2025 in Houston. IgA nephropathy is a progressive autoimmune disease affecting young individuals, with no current cure and a significant risk of renal failure.

rttnews·
4502
0.00%
US
TAK
+2.19%
rttnews·
4502
0.00%
US
TAK
+2.19%

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy | TAK Stock News

Takeda has presented new data from a Phase 1b study showing that mezagitamab (TAK-079) maintains stable kidney function in patients with primary IgA nephropathy for up to 18 months after treatment. The study reported significant reductions in proteinuria and serum Gd-IgA1 levels, with no serious adverse events observed. Takeda is advancing mezagitamab into Phase 3 trials for IgA nephropathy and immune thrombocytopenia, following its recent Orphan Drug and Breakthrough Therapy designations.

StockTitan·
US
TAK
+2.19%
4502
0.00%
StockTitan·
US
TAK
+2.19%
4502
0.00%

Takeda’s Earnings Call: Mixed Outlook Amid Challenges

Takeda Pharmaceutical Company's recent earnings call revealed a mixed outlook, showcasing strong pipeline advancements and strategic partnerships, but overshadowed by significant losses from VYVANSE's generic impact and currency headwinds. The company reported a 5.3% growth in launch products and positive Phase III results for rusfertide and oveporexton. However, VYVANSE's revenue loss of approximately JPY 100 billion and currency impacts led to a reduction in profit guidance. Despite challenges, Takeda remains optimistic about growth in the second half of the fiscal year, driven by innovation and strategic collaborations.

Tip Ranks·
4502
0.00%
Tip Ranks·
4502
0.00%

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

Protagonist Therapeutics, Inc. announced four presentations on rusfertide at the 67th Annual ASH Meeting in Orlando, Florida, from December 6-9, 2025. The presentations will focus on clinical data from the Phase 3 VERIFY study regarding rusfertide's efficacy and safety in treating polycythemia vera. Notable presentations include an oral session by Andrew Kuykendall, MD, and several poster sessions featuring analyses of patient-reported outcomes and long-term treatment results. Protagonist is advancing its drug development pipeline, including rusfertide and icotrokinra, in collaboration with Takeda Pharmaceuticals and Johnson & Johnson.

MorningStar·
4502
0.00%
US
JNJ
+2.88%
MorningStar·
4502
0.00%
US
JNJ
+2.88%